Payment overview · 2025
General Payments
2 reported records · 2 companies
Healthcare provider profile · identity verified
Allopathic & Osteopathic Physicians|General Practice · OLD BRIDGE, NJ · NPI 1265442875
Verified facts
CMS Open Payments records show Babar Mirza, MD received $35.46 in general payments during 2025 across 2 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 50.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
2 reported records · 2 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $18.00 | 50.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.46 | 49.2% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $35.46 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $17.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 448 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 414 | 137 |
| Metformin Hcl | Metformin Hcl | 330 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 300 | 90 |
| Losartan Potassium | Losartan Potassium | 298 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 286 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 281 | 79 |
| Simvastatin | Simvastatin | 266 | 81 |
| Lisinopril | Lisinopril | 221 | 69 |
| Metoprolol Tartrate | Metoprolol Tartrate | 215 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 186 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 131 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 125 | 42 |
| Alprazolam | Alprazolam | 112 | 35 |
| Omeprazole | Omeprazole | 108 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 33 |
| Allopurinol | Allopurinol | 107 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 103 | 34 |
| Alendronate Sodium | Alendronate Sodium | 101 | 42 |
| Carvedilol | Carvedilol | 94 | 35 |
| Montelukast Sodium | Montelukast Sodium | 94 | 35 |
| Furosemide | Furosemide | 83 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 80 | 21 |
| Glimepiride | Glimepiride | 74 | 27 |
| Cefuroxime | Cefuroxime Axetil | 60 | 53 |
| Finasteride | Finasteride | 60 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 55 | 17 |
| Eliquis | Apixaban | 54 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 21 |
| Gabapentin | Gabapentin | 53 | 19 |
| Famotidine | Famotidine | 51 | 15 |
| Valsartan | Valsartan | 48 | 14 |
| Sertraline Hcl | Sertraline Hcl | 44 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 43 | 12 |
| Donepezil Hcl | Donepezil Hcl | 42 | 19 |
| Jardiance | Empagliflozin | 41 | 11 |
| Repaglinide | Repaglinide | 41 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 40 | 14 |
| Fluocinonide | Fluocinonide | 39 | 21 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 19 |
| Metformin Hcl Er | Metformin Hcl | 37 | 11 |
| Synthroid | Levothyroxine Sodium | 37 | 11 |
| Enalapril Maleate | Enalapril Maleate | 35 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 16 |
| Atenolol | Atenolol | 33 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | 24 |
| Mupirocin | Mupirocin | 32 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Lovastatin | Lovastatin | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 27 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Nabumetone | Nabumetone | 30 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 18 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 12 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 26 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 21 |
| Irbesartan | Irbesartan | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 12 |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Desloratadine | Desloratadine | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 17 | 17 |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Potassium Chloride | Potassium Chloride | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Glipizide Er | Glipizide | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Prednisone | Prednisone | 11 | 11 |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $35.46 · 2 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | REXULTI, XIFAXAN | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error